AG真人官方

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (鈥淎mylyx鈥� or the 鈥淐ompany鈥�) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares of common stock are being offered by Amylyx. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Amylyx from this offering are expected to be $175.0 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the underwriters鈥� option to purchase additional shares.

Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, for:

• Avexitide commercial readiness;
• Research and development; and
• Working capital and other general corporate purposes.

The offering is expected to close on or about September 11, 2025, subject to the satisfaction of customary closing conditions.

Leerink Partners and Guggenheim Securities are acting as lead bookrunning managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

The shares described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-285525) that was filed with the Securities and Exchange Commission (the 鈥淪EC鈥�) on March 4, 2025 and declared effective by the SEC on March 26, 2025. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement.

A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on September 9, 2025, and are available on the SEC鈥檚 website located at . A final prospectus supplement containing additional information relating to the offering and accompanying prospectus will be filed with the SEC and will be available on the SEC鈥檚 website at . When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected]; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of that state or jurisdiction.

About Amylyx Pharmaceuticals

Amylyx鈥� mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, Amylyx sees opportunities and pursues them with urgency, rigorous science, and unwavering commitment to the communities it serves. Amylyx is currently focused on three investigational therapies across several endocrine and neurodegenerative diseases in which it believes it can make the greatest impact.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including with respect to the completion of the offering, the potential exercise by the underwriters of the option to purchase additional shares, the anticipated closing date of the offering, the expected gross proceeds from the offering and the expected use of proceeds from the offering. No assurance can be given that the offering will be completed. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Any forward-looking statements in this press release are based on management鈥檚 current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Amylyx鈥� SEC filings, including Amylyx鈥� Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 and its subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Amylyx.

View source version on businesswire.com:

Media

Amylyx Media Team

(857) 320-6191

[email protected]

Investors

Lindsey Allen

(857) 320-6244

[email protected]

Source: Amylyx Pharmaceuticals, Inc.